This company belongs to India and is a pharma company with a product line that contains therapeutic segments like gynaecology, orthopaedics, dermatology, and childcare. This company operates its business in the form of branded pharmaceuticals and has expanded its product line through organic and inorganic means.
The shares of Jagsonpal Pharma are currently trading at Rs. 241 . 16, by 6.88%. The company has a market capitalization of Rs. 1,588.06 crore. The stock’s 52 week high is Rs. 264.50 and its 52 week low is Rs. 155.00. In the past 6 months the stock has delivered a return of 32.73%.
What’s The News?
Jagsonpal Pharmaceuticals entered into the BTA with Group Pharmaceuticals on 23rd September, 2026, wherein it is stated that it will purchase the Wellness Portfolio of the seller on a going concern basis through a slump sale. Through the deal, the products, assets, contracts, employees and other arrangements pertaining to the business will be transferred to Jagsonpal Pharmaceuticals.
The acquisition is part of Jagsonpal’s strategy to strengthen its pharmaceutical portfolio, expand its presence across complementary therapeutic segments and increase its market reach. The company plans to integrate the acquired portfolio with its existing commercial platform and use its distribution network to generate operating synergies.
Deal Structure
This deal has been made in such a way that the transaction is on a going concern basis in the form of a slump sale arrangement. Jagsonpal Pharmaceuticals will pay Rs. 23.7 crore as a part of the deal to acquire the Wellness Portfolio from Group Pharmaceuticals. Additionally, there is also a performance contingent component where the company will have to pay up to Rs. 23 crore as a performance contingent payment during FY2027-28.
In this regard, the highest possible consideration for the transaction will be Rs. 46.7 crore. In relation to the transaction structure, the entire amount will not be paid at one go, as the extra consideration is based on the sales performance of the portfolio in FY28. The sales figure from the Wellness Portfolio for FY26 was Rs. 24.6 crore.
Strategic Rationale
The acquisition will give Jagsonpal access to an established portfolio and existing market presence while allowing the company to leverage its existing commercial infrastructure. Management expects the combination to create operating synergies and cross-selling opportunities across its portfolio.
Jagsonpal’s management stated that the acquisition is intended to strengthen its presence in complementary therapeutic segments, particularly women’s healthcare, while remaining consistent with its focused and asset-light approach to growth. The company also plans to expand its field force and strengthen its pan-India presence as the acquired portfolio is integrated.
Financial performance
Looking at the quarterly results of Jagsonpal Pharmaceuticals Limited, the company’s standalone revenue from operations stood at Rs. 82.23 crore in Q1 FY27, compared with Rs. 75.61 crore in Q1 FY26, registering a growth of around 8.76% YoY. On a sequential basis, revenue increased by around 28.08% from Rs. 64.20 crore in Q4 FY26. Total income stood at Rs. 85.07 crore in Q1 FY27, compared with Rs. 78.44 crore in Q1 FY26 and Rs. 67.37 crore in Q4 FY26.
In Q1 FY27, Jagsonpal Pharmaceuticals reported an operating EBITDA of Rs. 19.10 crore, compared with Rs. 15.72 crore in Q1 FY26, registering a growth of around 21.4% YoY. The EBITDA margin improved to 23.2% in Q1 FY27 from 20.8% in the corresponding quarter of the previous year. The improvement was supported by operating leverage and better medical representative productivity.
The company’s profit before tax stood at Rs. 17.68 crore in Q1 FY27, compared with Rs. 14.43 crore in Q1 FY26, registering a growth of around 22.5% YoY. On a sequential basis, PBT increased by around 50.39% from Rs. 11.76 crore in Q4 FY26.
In Q1 FY27, Jagsonpal Pharmaceuticals reported a net profit of Rs. 13.19 crore, compared with Rs. 10.80 crore in Q1 FY26, registering a growth of around 22.18% YoY. On a QoQ basis, net profit increased by around 50.53% from Rs. 8.76 crore in Q4 FY26. The company’s basic EPS stood at Rs. 2.00 in Q1 FY27, compared with Rs. 1.60 in Q1 FY26 and Rs. 1.33 in Q4 FY26.
Completion Timeline and Other Details
The transaction is expected to be completed on or before November 1, 2026, subject to the fulfilment of conditions precedent and other contractual terms under the BTA. The company has stated that the transaction does not constitute a related-party transaction, and none of the promoters, promoter group or group companies has an interest in Group Pharmaceuticals or the Wellness Portfolio.
The company has also stated that no governmental or regulatory approvals are required for the acquisition. The transaction remains subject to completion of the conditions specified in the BTA.
Investor Perspective
The acquisition gives Jagsonpal an opportunity to expand its product portfolio and market presence without paying the entire potential consideration upfront. Of the maximum Rs. 46.7 crore, Rs. 23.7 crore is payable at closing, while the remaining up to Rs. 23 crore is linked to FY28 sales performance. This makes the final acquisition cost partly dependent on the future performance of the acquired portfolio.
Going forward, investors can track the completion of the transaction, integration of the Wellness Portfolio, revenue contribution, sales growth during FY28 and the extent to which the performance-linked consideration becomes payable.